Mode
Text Size
Log in / Sign up
N/A N=121 Randomized Single-blind Supportive Care

BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal

Gynecologic Cancer · Gastrointestinal Cancer

Enrolled (actual)
121
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Feasibility of the BOLSTER Intervention — 73; 22 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
BOLSTER (Behavioral); Enhanced Discharge Planning (EDP) (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Dana-Farber Cancer Institute
Primary completion
Jun 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Feasibility of the BOLSTER Intervention
73; 22
SECONDARY
Acceptability of the BOLSTER Intervention
14; 8; 6; 2; 2; 0

Summary

This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their caregivers after a hospitalization.

Eligibility Criteria

Patient inclusion criteria

  • Adults (≥18 years old);
  • GYN or GI cancers receiving anti-neoplastic therapy;
  • Hospitalized, recently hospitalized (i.e. within the first 2 visits after a hospitalization), or recent outpatient placement of tube, line, or drain (e.g. PleurX catheter);
  • Plan to receive ongoing care at DFCI;
  • Willingness to be audio taped for the study (for monitoring of study fidelity).
  • Have complex care needs (e.g. an ostomy, ileostomy, a gastric tube, percutaneous nephrostomy tubes, a PleurX catheter, or need for total parenteral nutrition)

Patient exclusion criteria

  • Unable to read and respond to questions in English;
  • Cognitive impairment;
  • Unable to complete the baseline interview;
  • Plan for immediate hospice referral

Caregiver inclusion criteria

  • Adults (≥18 years old);
  • Family member or friend of an eligible patient;
  • Willingness to be audio taped for the study (for monitoring of study fidelity);
  • Willingness to participate in study visits

Caregiver exclusion criteria:

  • Unable to read and respond to questions in English,
  • Cognitive impairment
  • Unable to complete the baseline interview
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03367247). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search